BAC2021 banner thin Veertly(3).png

October 1 in Heidelberg

The ways in which we treat diseases are becoming more and more innovative, with the biotech industry demonstrating its full potential in the development of new ways to treat patients.

Our industry is constantly inventing, validating, and developing new drug modalities such as antibody-drug conjugates, RNA therapeutics, targeted degradation, gene editing, oligonucleotides and various combinations of these and other tools to address pathophysiological conditions.

Collaboration among industry, academia, regulatory, clinician and patient communities, as well as ad hoc funding and investment frameworks are essential to bring these solutions to the patients.

This year Annual Conference presents some of these biotechnology-driven new therapeutical approaches and partnership models for successful drug development.

Call for Poster is open!

When: 1. October 2021 9:00 - 17:00

Where:  Halle02, Zollhofgarten 2, 69115 Heidelberg

AGENDA (9:00 - 17:00)

08:30

Registration

09:00

Welcome & introduction

09:15

Keynote: “Next generation Immunotherapy”
Holger Kissel, BioNTech SE, Vice President Business Alliances

09:50

Dirk Grimm, University of Heidelberg, Professor and Group Leader
“The fast and the curious – high-throughput in vitro and in vivo interrogation of
AAV capsid libraries”

Christiane Kofink, Boehringer Ingelheim RCV & CoKG, Vienna, Principal Scientist
“The discovery of the first selective and orally bioavailable SMARCA2 degrader BI-0284”

10:30

Break

11:00

Ivan Đikić, Goethe University Frankfurt, Professor
“PROXIDRUGS: new therapeutic options for numerous diseases"

Claus Kremoser, WMT Therapeutics AG, Co-Founder and Chairman of the Board
“Targeting Cancer Metabolism to foster Immune Attack on Solid Tumours”

Michael Zimmermann, EMBL, Group Leader
“Identifying microbiome contributions to drug metabolism and toxicity”

12:00

Lunch

13:00

Parallel Workshops:

“Futureproofing your Process Development” hosted by Cytiva.

How can you balance innovation, speed and robustness to accelerate your process development? Find out more in this workshop.

“Innovative technologies and statistical methods for successful drug development” hosted by Cytel.

Explore technological solutions which enables cross-functional teams to optimize speed, cost and probability of success in drug development. And discover which Bayesian approaches can be used from preclinical to post-authorization to support orphan drug development.

14:10

Keynote: “Development of Bulevirtide/Hepcludex®, the first approved medication to treat chronic Hepatitis D infections.”
Florian Vogel, MYR (Gilead Sciences Inc.), Chief Commercial Officer
Stephan Urban, Heidelberg University Hospital, Head of

the Translational Virology Unit

15:00

Happy Hour & Speed-Networking

17:00

Closing

If you cannot come to Heidelberg, you can join the complete conference  remotely!

The conference is an event organised for BioRN members, associated and friends.

Since 2009, each year the BioRN Annual Conference has been a valuable source of top information, lively discussions and networking opportunities with international experts from different fields of the life sciences.

Sponsors

boehringer-ingelheim-logo-e1522070562631
2000px-Hoffmann-La_Roche_logo.svg.png

Conference

Supporter

AbbVie-Logo-EPS-vector-image (2).png
Merck_LOGO_highres_RGB_VM.jpg
cytiva_logo_hz_color_pos_rgb.jpg

Workshop Partner

Cytel_Logo_Cobalt_blue_200px (1).png

Key Public Partner

TP-Logo.png